FIFTH AMENDMENT TO THE DEVELOPMENT ALLIANCE AND SUPPLY AGREEMENTDevelopment Alliance and Supply Agreement • August 3rd, 2010 • Stereotaxis, Inc. • Electromedical & electrotherapeutic apparatus
Contract Type FiledAugust 3rd, 2010 Company IndustryThis fifth amendment (“Fifth Amendment”) is made effective as of July 30, 2010 and amends the Development Alliance and Supply Agreement dated May 7, 2002 between Biosense Webster, Inc. (“Biosense Webster”) and Stereotaxis, Inc. (“Stereotaxis”) (the “Master Collaboration Agreement”), as amended previously by: (i) the Amendment to Development and Supply Agreement dated November 3, 2003 (the “First Amendment”) (the Master Collaboration Agreement and First Amendment collectively referred to as the “Amended Master Agreement”); (ii) the side letter between the parties dated November 3, 2003, regarding research and development (the “R&D Side Letter”); (iii) the Alliance Expansion Agreement dated May 4, 2007 (“Expansion Agreement”); (iv) four side letters between the parties, each dated May 4, 2007, whose subject matter was, respectively, CARTO® Pro RMT, Third Party Collaboration Rights, Exclusivity and the meaning of Customers in the Non-Localized Alliance (collectively, the “2007 Side Letter
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED AND SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SIXTH AMENDMENT AND CATHETER AND MAPPING SYSTEM...Development Alliance and Supply Agreement • March 11th, 2011 • Stereotaxis, Inc. • Electromedical & electrotherapeutic apparatus
Contract Type FiledMarch 11th, 2011 Company Industry
FOURTH AMENDMENT TO THE DEVELOPMENT ALLIANCE AND SUPPLY AGREEMENT Between BIOSENSE WEBSTER, INC. AND STEREOTAXIS, INC.Development Alliance and Supply Agreement • May 7th, 2010 • Stereotaxis, Inc. • Electromedical & electrotherapeutic apparatus
Contract Type FiledMay 7th, 2010 Company IndustryThis fourth amendment (“Fourth Amendment”) is made effective as of May 1, 2010 and amends the Development Alliance and Supply Agreement dated May 7, 2002 between Biosense Webster, Inc. (“Biosense Webster”) and Stereotaxis, Inc. (“Stereotaxis”) (the “Master Collaboration Agreement”), as amended previously by: (i) the Amendment to Development and Supply Agreement dated November 3, 2003 (the “First Amendment”) (the Master Collaboration Agreement and First Amendment collectively referred to as the “Amended Master Agreement”); (ii) the side letter between the parties dated November 3, 2003, regarding research and development (the “R&D Side Letter”); (iii) the Alliance Expansion Agreement dated May 4, 2007 (“Expansion Agreement”); (iv) four side letters between the parties, each dated May 4, 2007, whose subject matter was, respectively, CARTO® Pro RMT, Third Party Collaboration Rights, Exclusivity and the meaning of Customers in the Non-Localized Alliance (collectively, the “2007 Side Letter
FIFTH AMENDMENT TO THE DEVELOPMENT ALLIANCE AND SUPPLY AGREEMENT BETWEEN BIOSENSE WEBSTER, INC. AND STEREOTAXIS, INC.Development Alliance and Supply Agreement • July 30th, 2010 • Stereotaxis, Inc. • Electromedical & electrotherapeutic apparatus
Contract Type FiledJuly 30th, 2010 Company IndustryThis fifth amendment (“Fifth Amendment”) is made effective as of July 30, 2010 and amends the Development Alliance and Supply Agreement dated May 7, 2002 between Biosense Webster, Inc. (“Biosense Webster”) and Stereotaxis, Inc. (“Stereotaxis”) (the “Master Collaboration Agreement”), as amended previously by: (i) the Amendment to Development and Supply Agreement dated November 3, 2003 (the “First Amendment”) (the Master Collaboration Agreement and First Amendment collectively referred to as the “Amended Master Agreement”); (ii) the side letter between the parties dated November 3, 2003, regarding research and development (the “R&D Side Letter”); (iii) the Alliance Expansion Agreement dated May 4, 2007 (“Expansion Agreement”); (iv) four side letters between the parties, each dated May 4, 2007, whose subject matter was, respectively, CARTO® Pro RMT, Third Party Collaboration Rights, Exclusivity and the meaning of Customers in the Non-Localized Alliance (collectively, the “2007 Side Letter
THIRD AMENDMENT TO THE DEVELOPMENT ALLIANCE AND SUPPLY AGREEMENTDevelopment Alliance and Supply Agreement • March 15th, 2010 • Stereotaxis, Inc. • Electromedical & electrotherapeutic apparatus
Contract Type FiledMarch 15th, 2010 Company IndustryThis third amendment (“Third Amendment”) is made effective as of December 21, 2009 and amends the Development Alliance and Supply Agreement dated May 7, 2002 between Biosense Webster, Inc. (“Biosense Webster”) and Stereotaxis, Inc. (“Stereotaxis”) (the “Master Collaboration Agreement”), as amended previously by: (i) the Amendment to Development and Supply Agreement dated November 3, 2003 (the “First Amendment”) (the Master Collaboration Agreement and First Amendment collectively referred to as the “Amended Master Agreement”); (ii) the side letter between the parties dated November 3, 2003, regarding research and development (the “R&D Side Letter”); (iii) the Alliance Expansion Agreement dated May 4, 2007 (“Expansion Agreement”); (iv) four side letters between the parties, each dated May 4, 2007, whose subject matter was, respectively, CARTO® Pro RMT, Third Party Collaboration Rights, Exclusivity and the meaning of Customers in the Non-Localized Alliance (collectively, the “2007 Side Le
EXPLANATORY NOTE: “*” INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED AND SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SECOND AMENDMENT TO DEVELOPMENT ALLIANCE AND SUPPLY...Development Alliance and Supply Agreement • November 10th, 2008 • Stereotaxis, Inc. • Electromedical & electrotherapeutic apparatus
Contract Type FiledNovember 10th, 2008 Company IndustryThis second amendment (“Second Amendment”) is made effective as of this 18th day of July, 2008, and amends that certain Development Alliance and Supply Agreement dated May 7, 2002 between Biosense Webster, Inc. (“Biosense Webster”) and Stereotaxis, Inc. (“Stereotaxis”) (the “Master Collaboration Agreement”), as amended previously by (i) that certain Amendment to Development and Supply Agreement dated November 3, 2003 (the “First Amendment”) (the Master Collaboration Agreement and First Amendment collectively referred to as the “Amended Master Agreement”), (ii) that certain side letter between the parties dated November 3, 2003, regarding research and development (the “R&D Side Letter”), (iii) that certain Alliance Expansion Agreement dated May 4, 2007 (“Expansion Agreement”) and (iv) four side letters between the parties, each dated May 4, 2007, whose subject matter was, respectively, CARTO Pro RMT, Third Party Collaboration Rights, Exclusivity and the meaning of Customers in the Non-L
SEVENTH AMENDMENT TO THE DEVELOPMENT ALLIANCE AND SUPPLY AGREEMENTDevelopment Alliance and Supply Agreement • March 15th, 2012 • Stereotaxis, Inc. • Electromedical & electrotherapeutic apparatus
Contract Type FiledMarch 15th, 2012 Company IndustryThis Seventh Amendment to Development Alliance and Supply Agreement (this “Amendment”) is made and entered into on December 5, 2011 (the “Effective Date”) by and between Biosense Webster, Inc., a California corporation, having a place of business at 3333 Diamond Canyon Road, Diamond Bar, California 91765 (“Biosense”) and Stereotaxis, Inc., a Delaware corporation, having a principal place of business at 4320 Forest Park Avenue, St. Louis, Missouri 63108 (“Stereotaxis”).
by and betweenDevelopment Alliance and Supply Agreement • May 12th, 2004 • Stereotaxis, Inc. • Electromedical & electrotherapeutic apparatus
Contract Type FiledMay 12th, 2004 Company Industry
EIGHTH AMENDMENT TO DEVELOPMENT ALLIANCE AND SUPPLY AGREEMENTDevelopment Alliance and Supply Agreement • June 25th, 2018 • Stereotaxis, Inc. • Electromedical & electrotherapeutic apparatus
Contract Type FiledJune 25th, 2018 Company IndustryThis Eighth Amendment (“Amendment”) is made effective as of the date of the last signature below, between Biosense Webster, Inc. (“Biosense”) with an address at 33 Technology Drive, Irvine, California 92618 and Stereotaxis, Inc. (“Stereotaxis”) with an address at 4320 Forest Park Avenue, St. Louis, Missouri 63108.